1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Taiwan Pharmaceuticals and Healthcare Report Q1 2016

Taiwan Pharmaceuticals and Healthcare Report Q1 2016

  • December 2015
  • -
  • Business Monitor International
  • -
  • 103 pages

Includes 3 FREE quarterly updates

BMI View:

The potential the Taiwanese pharmaceutical sector holds for overall economic growth will seecontinued investment by the government to support local drugmakers. This will gain in importance ascommercial opportunities in China's healthcare sector remain less affected by the overall slowdown in theeconomy. In addition, Taiwan's biomedical institutes and partnerships with multinational pharmaceuticalfirms will support domestic drugmakers in moving outward and up the value chain.

Headline Expenditure Projections

- Pharmaceuticals: TWD167.7bn (USD5.5bn) in 2014 to TWD175.1bn (USD5.5bn) in 2015; +4.4% inlocal currency terms and -0.1% in US dollar terms.

- Healthcare: TWD1,005.4bn (USD33.2bn) in 2014 to TWD1,046.8bn (USD33.0bn) in 2015; +4.1% inlocal currency terms and -0.4%% in US dollar terms.

Table Of Contents

Taiwan Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View ... 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Taiwan 2013-2019) 7
SWOT 9
Industry Forecast .. 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Taiwan 2011-2019) 12
Healthcare Market Forecast .. 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Taiwan 2011-2019) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Taiwan 2011-2019) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Taiwan 2011-2019) . 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Taiwan 2011-2019) 20
Patented Drug Market Forecast . 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Taiwan 2011-2019) 23
Generic Drug Market Forecast .. 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Taiwan 2011-2019) . 25
OTC Medicine Market Forecast . 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Taiwan 2011-2019) 28
Pharmaceutical Trade Forecast . 29
Table: Pharmaceutical Trade Data And Forecasts (Taiwan 2013-2019) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Taiwan 2013-2019) 31
Industry Risk Reward Index . 32
Asia Pacific Risk/Reward Index .. 32
Taiwan Risk/Reward Index 39
Rewards ... 39
Risks 40
Regulatory Review 41
Table: Medicine Categories In Taiwan . 42
Table: Examples Of Controlled Drugs In Taiwan 43
Intellectual Property Issues .. 43
Pricing Regime .. 44
Reimbursement Regime ... 46
Table: Reimbursement System in Taiwan . 46
Table: Drug Reimbursement Principles 48
Table: BNHI Spending By Type Of Outpatient Claims, As Percentage Of Total 49
Market Overview ... 52
Market Overview . 52
Healthcare Sector .. 52
Table: Sources Of Financing . 55
Table: Healthcare Resources (Taiwan 2009-2014) 56
Table: Healthcare Personnel (Taiwan 2009-2014) . 56
Table: Healthcare Activity (Taiwan 2009-2014) . 57
Research and Development 57
Clinical Trials ... 61
Epidemiology 62
Competitive Landscape 65
Research-Based Industry . 65
Table: Corporate Member Companies Of IRPMA . 65
Table: Multinational Market Activity . 66
Generic Drugmakers .. 66
Table: Top-20 Pharmaceutical and Biotechnology Firms In Taiwan According To Market Capitalisation (USDmn) . 67
Table: TGPA Members, 2012 . 69
Pharmaceutical Distribution 71
Pharmaceutical Retail Sector ... 71
Company Profile 73
GlaxoSmithKline (GSK) 73
Merck and Co 76
Novartis . 78
Pfizer 81
ScinoPharm Taiwan . 83
TaiGen .. 87
Yung Shin Pharmaceutical (YSP) 90
Demographic Forecast . 92
Table: Population Headline Indicators (Taiwan 1990-2025) 93
Table: Key Population Ratios (Taiwan 1990-2025) 93
Table: Urban/Rural Population and Life Expectancy (Taiwan 1990-2025) . 94
Table: Population By Age Group (Taiwan 1990-2025) 94
Table: Population By Age Group % (Taiwan 1990-2025) . 95
Glossary . 97
Methodology .. 99
Pharmaceutical Expenditure Forecast Model .. 99
Healthcare Expenditure Forecast Model . 99
Notes On Methodology .. 100
Risk/Reward Index Methodology . 101
Index Overview 102
Table: Pharmaceutical Risk/Reward Index Indicators 102
Indicator Weightings 103

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.